NT Mobile Menu

Search form


Gregory Rutecki, MD

Gregory Rutecki, MD

Posts by Author

New drugs that treat stubborn illness seen often in primary care lead this group of Top 5 Papers for 2014. Type 2 diabetes, cryptogenic stroke, and hep-C are key targets.

There are 2 FDA-approved sodium-glucose contransporter-2 inhibitors available in the United States. Here, a concise review of advantages/disadvantages and considerations in patient selection.

By clicking Accept, you agree to become a member of the UBM Medica Community.